21/08-2018 08:00:16: (NAVA) Navamedic ASA: Renews multiple key distribution agreements

Oslo, August 21, 2018 - Navamedic ASA (OSE: NAVA) today announced it has renewed three partnership agreements with Vitaflo International Limited, Allerderm Laboratories and Qiagen GmbH for continued Nordic distribution of important products within medical nutrition, dermatology and women's health.

"We are very pleased to announce a renewal of our partnerships with Vitaflo International, Allerderm Laboratories and Qiagen GmbH for continued distribution of their products in the Nordics. The agreements, which encompass several medical nutrition, dermatology and women's health products, means we will continue our joint efforts, building our positive results in the Nordic markets. These products are well in line with our key growth areas and strategic approach of continuing to strengthen our pharmaceutical products portfolio by entering solid, long-term partnerships," says Tom Rönnlund, Chief Executive Officer of Navamedic.
Navamedic will continue to market and distribute the products as part of its diversified pharmaceutical and healthcare portfolio, using existing sales channels, licensing- and distribution rights. The distribution agreements with Vitaflo International for medical nutrition products helping patients with different metabolic deficiency diagnoses and with Qiagen for the premature birth diagnostic test Amnisure® have both been prolonged by five years, while the partnership with Allerderm Laboratories for distribution of several dermatology and allergy products has been renewed for three years.
"The renewal of these agreements underscores the strength and breadth of Navamedic's marketing and distribution channels, as well as our strong cooperation with our partners. Our continued hard work within the Nordic market has provided us with a solid footing that allows us to maintain and renew long-term partnerships, as well as seek out new ones as a trusted partner. We see great potential for the products and are very happy to continue our work under renewed agreements," says Rönnlund.

For further information, please contact:

Tom Rönnlund, CEO, Navamedic ASA
Telephone: +46 727 320 321

Q2 2018 på førstkommende fredag. Siste kvartalet der det skal sammenlignes mot Aspen omsetning.

Det er nå 3 år siden Navamedic kjøpte Observe Medical. SIPPI er klar for markedet og bør begynne å vise et økende salg de kommende kvartaler.

Sippi bør absolutt begynne å levere snart. Nå leverer de med enheten bluetooth og de mest vanlige PDMS systemene, så nå må det vel løsne snart.

Glem heller ikke de nye medikamentene som er lagt til etter Aspen exit:

Imdur med potensiale på 70-100 millioner.
Elimiron med mulig omsetning på 50-100 millioner.
Mysimba med mulig omsetning på 50-120 millioner.

Blir fine bidrag dette på Navamedic sin skalerbare forretningsmodell. Samtidig har de de siste årene gjort flere runder med
kostnadskutt. Dette bør bli synlig på de neste presentasjonene.

Noen som skal på fredag?

24/08-2018 07:24:27: (NAVA) Navamedic ASA: Q2 2018 results

Oslo, August 24, 2018 - Navamedic ASA (OSE: NAVA) reported revenues of NOK 45.2 million in the second quarter of 2018, down from NOK 89.7 million in the same period in 2017, following the planned discontinuation of the Aspen agreement. The company significantly strengthened the gross margin to 35%, compared to 22.7% in the same quarter last year, reflecting growth in higher margin products. Sippi® wireless connectivity to Patient Data Monitoring Systems (PDMS) was completed during the quarter, with a solid test backlog of hospitals across Europe.

"The second quarter of 2018 marks important milestones for Navamedic, as we are seeing the results of our continued transition from dependence on a single partner to building a strong base portfolio of license and distribution agreements with longer contractual periods, significantly better gross margins, and strong growth potential. By launching new, innovative brands with good margins, such as the anti-obesity drug Mysimba, we are continuing our journey to position our company for future growth and profitability," says Tom Rönnlund, Chief Executive Officer of Navamedic.

Revenues in the second quarter of 2018 were NOK 45.2 million, a decrease from NOK
89.7 million in the corresponding quarter last year. The gross margin improved to 35.0%, up from 22.7% in Q2 2017, reflecting growth in higher margin products. The Navamedic group's EBITDA for the second quarter was NOK 3.5 million, down from NOK 5.5 million in Q2 2017.

"The anti-obesity drug Mysimba, which has seen significant market uptake, is gaining headlines and receives solid feedback from clinicians and patients across the Nordics, is one example of our strategy to focus on launching new and innovative treatments that drive our return to profitability. We continue to see great growth opportunities for this long-awaited innovation treating serious, and to a large extent, unmet medical need," says Rönnlund, and continues:

"We also look forward to the upcoming anticipated launch of Elmiron, for the treatment of interstitial cystitis, and to continuing our work to return to profitable growth and to add to our pipeline of new and exciting original products, with launches scheduled for the coming 6-18 months," says Rönnlund

During the quarter, the company also announced the finalisation of the Sippi® wireless connectivity solution to Patient Data Monitoring Systems (PDMS), now under testing at European hospitals. Sippi® is a new standard for urine monitoring enabling automated digital measurement. The system represents a new and improved way of monitoring urine output, the last manual and non-digitalised vital parameter within the Intensive Care Unit (ICU).

"We have a back-log of clinics across Europe now initiating tests of the first wireless PDMS-connected digital urinometer on the market. With successful outcomes from these, we see a great opportunity to begin the era of setting new standards in the field of urine volume monitoring in intensive care and other wards in hospitals across Europe and the world. As previously announced, we have appointed a renowned, internationally established adviser to ensure we create the best possible conditions for the global launch of Sippi® and accelerate the successful market introduction of this innovative technology," says Tom Rönnlund

The company is hosting a presentation of the second quarter 2018 figures at Felix Konferansesenter, Aker Brygge, Oslo, Friday 24 August. The presentation will start at 08.00. The presentation will be webcasted live on www.navamedic.com.

For further information, please contact:

Tom Rönnlund, CEO, Navamedic
Telephone: +46 727 320 321

Ser jo ikke så ille ut dette!

The company significantly strengthened the gross margin to 35%, compared to 22.7%, up from 22.7% in Q2 2017
The Navamedic group's EBITDA for the second quarter was NOK 3.5 million

"The anti-obesity drug Mysimba, which has seen significant market uptake
"We have a back-log of clinics across Europe now initiating tests of the first wireless PDMS-connected digital urinometer on the market.

Her er det som gjør investering i NAVA spennende:
"Sippcoat® use in body fluid handling system to prevent bacteria migration.
Global addressable market of > 500 million urine bags annually"

Hva vil NAVA verdsettes til den dagen dette er en realitet?

"Based on ongoing new launches and our pipeline of additional products, the company
targets a sales turnover of at least NOK 400 million for the Pharma and Healthcare
segment in a three to five year perspective.

With wireless PDMS communication feature and multimarket growth platform in place
the company is pursuing the long-term annual revenue potential for Sippi®, expected
to be in excess of NOK 250 million"

Forhåpentligvis siste idiot overskrift på Hegnar for Navamedic på en stund..?


Navamedic halverte inntektene
- 2. kvartal 2018 markerer viktige milepæler for Navamedic, sier
Tom Rönnlund, administrerende direktør i Navamedic.

Artikkel av: Øystein Byberg
24. august 2018 - 07.39

Navamedic melder om et resultat etter skatt på 0,3 millioner kroner i 2. kvartal 2018, mot 0,5millioner kroner i samme periode året før.
Se kvartalspresentasjon LIVE her 08.00
Resultatet før skatt ble 0,4 millioner kroner, sammenlignet med minus 1,8 millioner kroner i fjor.
Driftsresultatet ble 2,1 millioner kroner, mot 2,3 millioner kroner året før.
EBITDA beløp seg til 3,5 millioner kroner, mot 5,5 millioner kroner i fjor.
Driftsinntektene beløp seg til 45,2 millioner kroner, sammenlignet med 90,0 millioner kroner i 2. kvartal 2017. Nedturen skjer i kjølvannet av utløpet av Aspen-avtalen.

- 2. kvartal 2018 markerer viktige milepæler for Navamedic, i det vi ser resultatene av overgangen fra å være avhengig av én enkeltstående partner til å bygge en sterk såle av lisens- og distribusjonsavtaler med lengre kontraktsperioder, bedre bruttomarginer og et sterkt vekstpotensial. Ved å lansere nye, innovative produkter med gode marginer, som for eksempel antifedme-medikamentet Mysimba, fortsetter vi reisen med å posisjonere selskapet for fremtidig vekst og lønnsomhet, sier Tom Rönnlund, administrerende direktør i Navamedic.

- Antifedmemedikamentet Mysimba, som har opplevd en sterk markedsvekst, har fått nyhetsoverskrifter og mottar sterk interesse fra leger og pasienter over hele Norden. Produktet er kun ett eksempel på vår strategi om å fokusere på lansering av nye, innovative behandlinger som vil føre oss tilbake til lønnsomhet. Vi fortsetter å se gode vekstmuligheter for dette innovative og etterlengtede produktet som behandler et stort og udekket behov, sier Rönnlund og fortsetter:
- Vi ser også frem til lanseringen av Elmiron for behandling av smertefull blæresyndrom, samtidig som vi fortsetter arbeidet vårt mot en lønnsom vekst og lanseringen av nye, spennende originalprodukter de kommende 6 til 18 månedene, sier Rönnlund

Med årlig omsetning på 400 millioner, 10% resultat og PE 15 så kan Navamedic verdsettes til 600 millioner/55 aksje.